SAN DIEGO–(BUSINESS WIRE)–June 9, 2005–Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon’s forthcoming Hepatitis-C (HCV) clinical trials in India. “The Apollo Hospital is undisputedly the most prestigious multi-specialty hospital in India and is the largest corporate hospital outside of the United States,” stated Mr. Sandeep Malik, President of Qualtran.

Dr. Vijay Kher, Senior Consultant of Nephrology at Apollo Hospital has been retained as the Principal Investigator for the trial. Dr. Kher, who has over 30 years of clinical experience, has been the recipient of numerous medical awards, and is credited with over 100 scientific publications. Following a Clinical and Research fellowship at Henry Ford Hospital, Detroit and the University of Cincinnati, Dr. Kher served as a visiting professor to several Universities, including the University of Cincinnati, Loyola University, Rutgers, and the University of Chicago.

Aethlon Chairman & CEO, James A. Joyce, stated, “The unfortunate reality is that 50% of Hepatitis-C patients who initiate the current standard of care fail this exceptionally toxic treatment regimen.” Joyce continued, “We clearly envision that our Hemopurifier(TM) treatment technology will improve patient outcomes as an adjunctive therapy, and will serve as an effective disease management tool as a stand alone treatment. In this regard, I thank our colleagues in India for providing us the opportunity to treat patients who are infected with this progressive disease,” concluded Joyce.

Aethlon further disclosed that biocompatibility studies of the Hemopurifier are under way, and the Company anticipates that the formal initiation of the trial will occur in mid-July. The near term goal will be to demonstrate safety and observe early efficacy markers, including viral load reduction as a result of the direct clearance of circulating HCV by the Hemopurifier. The patient treatment protocols developed for the trial were designed through a cooperative effort between Aethlon researchers and its regulatory advisors in both India and the United States. According to the World Health Organization, HCV is a global disease with approximately 170 million persons or 3% of the world’s population infected.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.